This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.

Hibi Kazushige0 个研究点目标入组 24 人开始时间: 2023年3月2日最近更新: 2024年5月27日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 <= 130age old（—）
性别: All

入选标准

•Must be 18 or more years of age
•- Japan mini dose escalation phase: Histological or cytological confirmation of a solid, malignant tumor refractory to standard therapies or for which no standard therapies exist (Recruiting of Japan mini dose escalation phase has ended).
•- Part B Dose Expansion cohorts B2 and B3: Histologically or cytologically documented Stage IIIB to IV non-small cell lung carcinoma (NSCLC) not amenable to curative surgery or radiation (Recruiting of cohort B3 has ended).
•- Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
•- Provision of archival tumor tissue sample or fresh tissue sample for Part B Dose-expansion cohorts B2 and B3. Provision of fresh tumor tissue sample and consent to undergo mandatory on-treatment biopsy for cohort B4.
•- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
•- Non-pregnant women and willingness of female participants to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of contraception
•- Adequate organ and bone marrow function measured within 28 days prior to first dose
•- Part B Dose Expansion Cohort B3 Additional Inclusion Criteria:
•- May have squamous or non-squamous NSCLC
•- Must have received at least one prior line of systemic therapy, - of which only one prior line of therapy contained approved anti-PD-1/PD-L1
•- Must have had IO acquired resistance
•- PD- L1 expression 1% or more documented
•- Part B Dose Expansion Cohort B2 Additional Inclusion Criteria:
•- May have squamous or non-squamous NSCLC
•- Must not have received prior systemic therapy including IO therapy in the first-line setting
•- PD-L1 expression 50% or more documented
•- Part B Dose Expansion Cohort B4 Additional Inclusion Criteria:
•- Must have received at least one but no more than two prior lines of systemic therapy, of which only one prior line of therapy contained an approved anti-PD-1/PD-L1
•- Must have had IO acquired resistance
•- There are no PD-L1 status requirements for this cohort

排除标准

•- Part B Dose Expansion: Patients with sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusions. Documented test result is mandatory for participants with non-squamous NSCLC histology. For participants with squamous NSCLC histology, testing is mandatory only if the participant is a never-smoker or in the presence of a mixed histology. (not applicable for the Japan mini dose escalation phase)
•- Part B Dose Expansion: Documented test result for any other known genomic alteration for which a targeted first line therapy is approved per local standard of care (SoC) (not applicable for the Japan mini dose escalation phase)
•- Part B Dose-expansion Cohort B4: documented HER2 amplification (unless a SoC including an anti-HER2 therapy has been received); testing is not mandatory if not required per local guidelines.
•- Unresolved toxicities of Grade 2 or more from prior therapy
•- Any prior Grade 3 or more immune-mediated adverse event (imAE) while receiving immunotherapy or any unresolved imAE Grade 2 or more
•- Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy
•- Symptomatic central nervous system (CNS) metastasis or leptomeningeal disease
•- History of symptomatic and objectively confirmed arterial (including myocardial infarction) or venous thromboembolic event within 6 months prior to the first dose of study intervention, unless participant is on treatment with adequate antithrombotic medication and is considered to be stable by the Investigator.
•- History of organ transplant or allogenic haematopoietic stem cell transplant
•- Infectious disease exclusions: Active infection including TB, HIV, hepatitis A, chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19 infection
•- History of clinically significant arrythmia as judged by the Investigator.
•- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, cardiomyopathy of any etiology, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled diabetes mellitus, unstable angina pectoris, history of myocardial infarction within the past 6 months, serious chronic gastrointestinal conditions associated with diarrhea, active non infectious skin disease. Part B Dose-expansion Cohort B4, medication-resistant ascites requiring drainage in the last 28 days prior the start of AZD7789 and/or the occurrence of active gastro-intestinal bleeding, as judged by the Investigator.
•- Active or prior documented autoimmune or inflammatory disorders, including inflammatory bowel disease (eg, colitis or Crohn's disease), diverticulitis (with the exception of diverticulosis), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis), Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.. Some exceptions have been specified in the protocol
•- Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
•- Major surgical procedure within 28 days prior to the first dose of study intervention or still recovering from prior surgery
•- Other invasive malignancy within 2 years prior to screening
•- Congenital long QT syndrome or history of QT prolongation associated with other medications that cannot be changed or discontinued based on a cardiologist assessment
•- Any previous tr

研究者

发起方

Hibi Kazushige

相似试验

招募中

1 期

A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic Non-small Cell Lung Canceron-Small-Cell Lung Carcinoma

JPRN-jRCT2031220297Hibi Kazushige18

进行中（未招募）

不适用

Ensayo clínico abierto de fase I/IIa para evaluar la dosis máxima tolerada, eficacia, seguridad y farmacocinética de BI 811283 en combinación con citarabina en pacientes con leucemia mieloide aguda no tratados previamente y que no sean elegibles para tratamiento intensivoAn open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myeloid leukaemia ineligible for intensive treatment

EUCTR2007-005684-10-ESBoehringer Ingelheim España S.A.169

进行中（未招募）

1 期

A trial to test the safety and efficacy of a new drug (human immune cells against COVID-19, administered intravenously) for patients with COVID-19 in need of treatment or at risk for severe COVID-19Patients who are tested positive for SARS-CoV-2 by PCR from upper or lower respiratory sites and are at increased risk for developing critical disease presenting with moderate disease-WHO ordinal scale 4 with at least one additional risk factor for disease progression or -WHO ordinal scale 5MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862

EUCTR2021-000417-16-DEniversity of Cologne51

进行中（未招募）

2 期

Investigator-initiated phase II trial to evaluate the efficacy and safety of Acotiamide in patients with esophagogastric junction outflow obstructio

JPRN-jRCT2071210072Ihara Eikichi42

已完成

1 期

A Phase I study to assess Reactogenicity, safety and immunogenicity of Biological E’s Liquid Hexavalent Vaccine when administered in healthy children of 16 to 24 months.

CTRI/2023/05/052319Biological E.Limited48